This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

Antibody Engineering

The Future of Monoclonal Antibodies - WHITEPAPER


Download the exclusive report

The monoclonal antibodies market continues to grow - according to BIS Research and Research and Markets, monoclonal antibodies (mAbs) are expected to make up just under half of the USD $22.7 billion biologics discovery market in 2025. Engineered or recombinant proteins including next generation antibody therapeutics are expected to contribute $3 billion to the market by 2025. This whitepaper looks at the current state and future of monoclonal antibodies, exploring:

  • FDA approved monoclonal antibodies approved for the first time in 2018

  • Five candidates for FDA approval during Q4 2018, or Q1 2019

  • Monoclonal antibodies in late stage clinical trials

  • Emerging trends in antibody therapeutics

  • The next generation of antibody therapeutics in the next 5-10 years

To download the exclusive report simply log in or register for an Informa Connect account, which will give you access to all our exclusive premium content.

Have any questions about the report or interested in sponsoring a future report? Email

Log in or Create an Informa Connect Account to Access this content

Creating an account also means you'll get special access to article updates and exclusive industry content.